

Source

Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Rituximab F(ab')₂.

Isotype

Mouse IgG1/kappa

Specificity

Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 µm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.


Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- 4-8°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.

SDS-PAGE

Anti-Rituximab Antibody (AY37) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.


Bioactivity-Elisa

Anti-Rituximab Antibodies (Neutralizing)—PK assay



Detection of rituximab by bridging ELISA in serum. Immobilized Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37) at 2 µg/mL, add increasing concentrations of rituximab (10% human serum) and then add Biotinylated Anti-Rituximab Antibody (Cat. No. RIB-BY35) at 1 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/mL.


Determination of Anti-Rituximab Antibodies Specificity



Demonstration of the specificity of Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37) to the rituximab.

Bioactivity-FACS

Anti-Rituximab Antibodies inhibited the binding of Rituximab to 293F-CD20



FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.019 µg/ml (Routinely tested).

Background

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.